Bonjour ,
Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.
% complété
%
2 Ce profil est validé par 2 label.
Company
Metabolys
30
EQ SCORE L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
Lyon, Auvergne-Rhône-Alpes, France
Send a message
Anglais
Metabolys
Anglais
- Metabolys is a biopharmaceutical company developing breakthrough treatments for metabolic diseases with a focus on NASH (Non-alcoholic Steatohepatitis). MTBL0036, the lead compound of Metabolys, is in the late stage of the preclinical phase of drug development.
- MTBL0036 is one of the most efficient oral molecules in development for the treatment of NASH. With an exceptional safety profile, it has been shown in mice to address multiple facets of NASH pathophysiology,...
- Metabolys is a biopharmaceutical company developing breakthrough treatments for metabolic diseases with a focus on NASH (Non-alcoholic Steatohepatitis). MTBL0036, the lead compound of Metabolys, is in the late stage of the preclinical phase of drug development.
- MTBL0036 is one of the most efficient oral molecules in development for the treatment of NASH. With an exceptional safety profile, it has been shown in mice to address multiple facets of NASH pathophysiology, including insulin sensitivity, inflammation, ballooning and lipid profile. In addition, synthesis and purification of MTBL0036 are simple processes which should allow an easy production scale-up.
- Once its safety is demonstrated in humans, MTBL0036 will undergo a phase IIa clinical study. Metabolys strategy is then to out-license its lead candidate to a major pharmaceutical company for phase III, registration and marketing.
- Thanks to its skilled and well experienced team in medicinal chemistry and metabolic diseases, Metabolys will at this time focus its effort and resources on the development of new drug candidates in the fields of NASH and type 2 diabetes. The company will continue to operate in its core business fuelling the drug pipeline and contributing to the fight against these progressing diseases.
- Metabolys is about extending the therapeutic indication of 2 molecules of its protfolio to oncology.
-
1
Followers
Team member(s)
Your request has been sent
Join this organization
Your request has been sent
Team member(s)
Our network
Your request has been sent
Join this network
Your message has been sent
Certifications
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not receive funding due to budget limits.
This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
1478 Entities
The InvestHorizon Accelerated label is for selected deep tech companies from the accelerator programme to facilitate series A funding.
This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
InvestHorizon is a programme financed by the European Commission in association with Eureka to foster investment readiness.
454 Entities
Communities
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding
for selected DEEP TECH companies.
2667 Members
The Access2EIC -Seal of Excellence community aims at gathering high potential European companies that received from the European Commission a “Seal of Excellence” certificate and European equity investors.
https://access2eic.eu/
2140 Members
Our history
Start in Jan. 2010
-
Jan. 2010
Initially, Metabolys had a mixed business model (drug discovery + service)
-
2011
Discovery of antidiabetic candidates
-
2016
Discovery of an anti-NASH candidate and service acctivity abandoned
-
2018
Identification of the molecular target
-
2021
Participation in the RESI Conference
to be continued ...